Amgen, India

Drugmaker Amgen to invest $200 million in India site, CEO says
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at the inauguration of the site on Monday.
US Drugmaker Amgen To Invest $200 Million In India
NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in southern India, with additional investments anticipated, CEO Robert Bradway announced during the site’s inauguration on February 24.
Amgen opens new technology & innovation site in Hyderabad, to invest $200 million
The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities for local talent.
Amgen Invests $200M in India Tech Hub to Boost AI-Driven Drug Development
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the sites inauguration,
Amgen opens new tech and innovation centre in Hyderabad with starting investment of $200m in 2025
US-based biopharma giant on Monday opened its new technology and innovation centre in Hyderabad with its CEO Robert Bradway announcing a $2.
Amgen plans $200M investment in India site, Reuters reports
Amgen (AMGN) plans to invest about $200M this year in its new technology center in southern India, with further investments planned, Reuters’
Amgen to invest $200 million in India site, CEO says
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert Bradway said at the inauguration of the site on Monday.
Amgen to invest over $200M in India tech facility: report
Amgen (NASDAQ:AMGN) reportedly plans to invest over $200M in its newly opened technology and innovation center in Hyderabad, India. The site, which was officially opened on Monday, is expected to employ around 2,
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Amgen injects $200m in Hyd with new tech centre
Hyderabad: US-based biopharma giant Amgen flagged off its first India investment with a new technology and innovation centre ...
US biotech firm Amgen’s $200 million tech and innovation centre in Hyderabad inaugurated by Telangana CM
Global biotech leader Amgen opened its $200 million technology and innovation centre in Hyderabad, a facility that will help ...
Amgen shares snapped six straight sessions of gains
Amgen (NASDAQ:AMGN) shares snapped six straight sessions of gains, as the stock ended 3% lower at $306.2 on Wednesday. The ...
Drugmakers tout AI efforts at conference amid US tariffs concerns
Drugmakers such as Amgen and contract manufacturers including Parexel highlighted AI's role in reducing the time taken to ...
High-profile biotech startup raises megaround, preps for move to Peninsula
Eikon is building a high-profile line of potential drugs. Its portfolio is led by EIK-1001, which is just rolling out a ...
PMLiVE20h
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Amgen’s Blincyto (blinatumomab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat certain cases of acute lymphoblastic leukaemia (ALL).